Investment Rating - The report maintains a "Buy" rating for Zai Lab (ZLAB.US/9688.HK) and slightly lowers the target price to $55 for US shares and HK$43 for Hong Kong shares [1][4]. Core Insights - In Q3 2024, Zai Lab's net loss significantly narrowed to $41.67 million, a decrease of 39.7% year-over-year and 48.1% quarter-over-quarter, primarily due to lower-than-expected selling and administrative expenses [1]. - Product revenue for Q3 2024 reached $101.8 million, representing a 47% year-over-year increase and a 1.7% quarter-over-quarter increase, aligning with consensus expectations [1]. - The gross margin for product sales was stable at 64.1%, with a slight decrease of 0.8 percentage points quarter-over-quarter [1]. - The company continues to see strong growth in Efgartigimod, with Q3 2024 revenue of $27.3 million, a remarkable increase of 458% year-over-year and 17.6% quarter-over-quarter [1]. - Zai Lab has achieved approximately 65% market potential coverage for Efgartigimod, with around 10,000 myasthenia gravis patients having used the drug, and a stable monthly addition of about 1,000 new patients [1]. Financial Summary - The report projects a narrowing of net loss to $260 million for 2024, with slight adjustments to the 2025 and 2026 net loss and profit forecasts based on updated financial information [1][4]. - Revenue forecasts for 2024, 2025, and 2026 are $402 million, $651 million, and $995 million respectively, with year-over-year growth rates of 50.6%, 62.2%, and 52.8% [4][5]. - The report anticipates that Zai Lab will continue to expand its product pipeline, with several key drugs expected to be commercialized in China by the end of 2024 and early 2025 [1][4]. Market Expectations - The current stock price for Zai Lab is $29.0, with a potential upside of 90% to the target price of $55.0 [2]. - The stock has a 52-week price range of $13.4 to $36.6, and the total market capitalization is approximately $2.885 billion [2]. - For the Hong Kong shares, the current price is HK$23.4, with a potential upside of 84% to the target price of HK$43.0 [3].

Summary of the Conference Call Company and Industry Overview - The conference call was focused on the performance of a biopharmaceutical company, specifically discussing its Q3 2024 results and future outlook. The company operates in the biopharmaceutical industry, with a focus on oncology and immunotherapy products. Key Points and Arguments 1. **Q3 Performance Highlights** - The company achieved total product revenue of $100 million, representing a year-over-year growth of 47% [1][3][12]. - Operating losses narrowed by 19% year-over-year, while net losses decreased by 40% [1][5][12]. - Sales of the product "Aigamod" reached $27.3 million in Q3, marking a significant achievement [1][15]. 2. **Product Pipeline and R&D Progress** - The company plans to submit at least four new product applications domestically within the next six months [2][4]. - Recent clinical trials for the drug "DL1310" showed an overall response rate (ORR) of 74% in small cell lung cancer patients, with a 100% ORR in patients with brain metastases [6][32]. - The company is advancing multiple candidates, including "GL3010" and "CL-1503," into clinical stages, with expectations for significant breakthroughs [4][28]. 3. **Market Strategy and Future Outlook** - The company aims for annual revenue growth of approximately 50% and targets $2 billion in revenue by 2025 [5][12]. - The management expressed confidence in the commercialization of "Aigamod" and other products, anticipating a strong market presence [10][11]. - The company is also focusing on expanding its global pipeline and optimizing operational efficiency [3][12]. 4. **Regulatory and Market Access** - The company participated in national health insurance negotiations, with expectations for favorable outcomes [15][19]. - The management highlighted the importance of market access for new products, particularly in the context of competitive pricing and reimbursement strategies [19][35]. 5. **Sales and Marketing Efforts** - The company has successfully established a presence in key hospitals, covering approximately 60% of the potential market for "Aigamod" [15][16]. - There is a growing trend of repeat prescriptions among physicians, indicating strong acceptance of the product [9][15]. Other Important but Possibly Overlooked Content - The company has a robust cash reserve of $716 million, which supports its strategic goals and ongoing development efforts [12]. - The management emphasized the need for continuous education and support for healthcare providers to enhance the adoption of their therapies [9][10]. - The competitive landscape is evolving, with potential challenges from generic products and market dynamics, particularly in the oncology sector [21][22]. - The company is exploring partnerships for certain products to enhance market access and distribution capabilities [37]. This summary encapsulates the key insights from the conference call, highlighting the company's performance, strategic direction, and market positioning within the biopharmaceutical industry.

Financial Data and Key Metrics Changes - Total net product revenue for Q3 2024 was $101.8 million, a 47% increase year-over-year from $69.2 million in Q3 2023 [46] - Net loss for Q3 2024 was $41.7 million, improving by 40% compared to a net loss of $69.2 million in Q3 2023 [53] - The company ended Q3 2024 with a cash position of $716.1 million, down from $730 million as of June 30, 2024 [54] Business Line Data and Key Metrics Changes - VYVGART net product revenue grew to $27.3 million in Q3 2024, up from $4.9 million in Q3 2023, driven by increased sales since its launch [47] - ZEJULA net product revenue increased 16% to $48.2 million, maintaining its position as the leading PARP inhibitor for ovarian cancer in China [48] - NUZYRA net product revenue grew 82% to $10 million, supported by NRDL listings for its formulations [49] Market Data and Key Metrics Changes - The commercial business in China is rapidly growing, with VYVGART on track to become a potential blockbuster product [7] - Approximately 10,000 patients have been treated with VYVGART since its launch, representing a small fraction of the 170,000 patients living with gMG in China [17] - The company expects to launch VYVGART Hytrulo for CIDP, which affects 50,000 patients in China, as soon as possible [22] Company Strategy and Development Direction - The company is focused on three strategic priorities: driving revenue growth, expanding the global pipeline, and enhancing operational efficiency [6] - Zai Lab aims to achieve at least five potential approvals over the next one to two years, including KarXT and bemarituzumab, both of which have blockbuster potential [10] - The company is on track to reach profitability by the end of 2025, supported by ongoing revenue growth and cost efficiency initiatives [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong momentum of VYVGART and the potential for continued growth in Q4 2024 [60] - The company is excited about the promising early data from ZL-1310, which shows a robust 74% objective response rate in patients with small cell lung cancer [31] - Management highlighted the importance of educating physicians about new treatment options and the potential for KarXT in the schizophrenia market [71] Other Important Information - The company has made significant advancements in its global pipeline, including the introduction of ZL-6301 and the development of ZL-1503 for atopic dermatitis [9][35] - Zai Lab is preparing for multiple product launches, including AUGTYRO and XACDURO, targeting specific cancer types and infections [26] Q&A Session Summary Question: VYVGART growth and Q4 expectations - Management noted that Q3 growth was driven by approximately 1,000 new patients initiated per month, with expectations for continued growth in Q4 [58][60] Question: Next steps for DLL3 - Management indicated that they are enrolling patients and capturing data for ZL-1310, with updates expected next year [64] Question: Impact of competitive landscape on KarXT - Management expressed excitement about the opportunity for KarXT and plans to move quickly towards submission and launch [70][71] Question: Internal discovery efforts and IL-17 updates - Management provided insights on the IL-13/IL-31 bispecific antibody and ongoing Phase 2 study for IL-17, with data expected early next year [75][76] Question: Competitive landscape for DLL3 - Management discussed the dynamic landscape for small cell lung cancer treatments and the significant market opportunity, estimating a total market potential of $7.5 billion in the US alone [90][91]

Financial Performance - For Q3 2024, product revenue net amounted to $101.8 million, a 47% increase year-over-year from $69.2 million in Q3 2023[2] - Total revenue for the three months ended September 30, 2024, was $102.265 million, a 47% increase compared to $69.228 million in the same period of 2023[26] - Product revenue for the nine months ended September 30, 2024, reached $289.102 million, up 44% from $200.889 million in the same period of 2023[29] - The net loss for Q3 2024 was $41.7 million, with a loss per share of $0.04, compared to a net loss of $69.2 million and a loss per share of $0.07 in Q3 2023[5] - Net loss for the nine months ended September 30, 2024, was $(175.419) million, a decrease of 26% compared to $(239.191) million in the same period of 2023[28] - Operating loss for the three months ended September 30, 2024, improved to $(67.853) million from $(83.570) million in the same period of 2023, representing a 19% reduction[30] - The adjusted operating loss for Q3 2024, excluding non-cash expenses, was $48.2 million[5] - The adjusted operating loss for the three months ended September 30, 2024, was $(48.187) million, compared to $(59.660) million in the same period of 2023[30] Product Revenue and Growth - The revenue from the product Weiwei Jia was $27.3 million in Q3 2024, up from $4.9 million in Q3 2023, attributed to sales growth since its launch in September 2023 and its inclusion in the NRDL from January 1, 2024[4] - The revenue from the product Zele was $48.2 million in Q3 2024, a 16% increase from $41.6 million in Q3 2023[4] - The company expects to commercialize three products in mainland China by the end of 2024 and plans to submit up to four new drug applications to the National Medical Products Administration within the next six months[2] - The company expects to commercialize SUL-DUR for treating HABP/VABP in adults by the end of 2024[12] - The company plans to submit a new drug application for KarXT for schizophrenia treatment in early 2025[13] Research and Development - R&D expenses for Q3 2024 were $66 million, compared to $58.8 million in Q3 2023, primarily due to increased upfront and milestone payments[5] - The global Phase 1 data for ZL-1310 (DLL3 ADC) indicates best-in-class potential in treating extensive-stage small cell lung cancer[2] - ZL-1310 (DLL3 ADC) achieved an objective response rate (ORR) of 74% across multiple dosing levels in a Phase 1 clinical trial for ES-SCLC, with good tolerability observed[8] - The Phase 3 clinical trial FORTITUDE-102 for Bemarituzumab (FGFR2b) has completed patient recruitment, exploring its use in first-line treatment for gastric cancer[8] - KarXT demonstrated a statistically significant reduction of 9.2 points in the PANSS total score compared to placebo in a Phase 3 study for schizophrenia, with a p-value of 0.0014[10] - ZL-1503 (IL-13/IL-31) is being explored as a new therapy for moderate to severe atopic dermatitis, with preclinical data presented at the EADV conference[10] - The company will initiate a global Phase 1 study for ZL-6301 (ROR1 ADC) in solid tumors in 2025[17] - The company is collaborating with argenx to explore Efgartigimod's potential in other IgG-mediated autoimmune diseases, with several global registration studies planned[14] - The company is participating in the Phase 3 clinical trial PANOVA-3 for local advanced pancreatic cancer, with data expected in Q4 2024[15] Financial Position - As of September 30, 2024, total cash and cash equivalents, short-term investments, and restricted cash amounted to $716.1 million, down from $730 million as of June 30, 2024[6] - As of September 30, 2024, cash and cash equivalents totaled $616.1 million, down from $790.2 million as of December 31, 2023, representing a decrease of approximately 22%[23] - Total assets decreased from $1,036.3 million on December 31, 2023, to $985.3 million on September 30, 2024, a decline of about 5%[23] - The total equity of the company decreased from $796.1 million as of December 31, 2023, to $667.7 million as of September 30, 2024, reflecting a reduction of approximately 16%[25] - The company reported an accumulated loss of $2.37 billion as of September 30, 2024, compared to $2.20 billion as of December 31, 2023, indicating an increase in losses of about 8%[25] - The company had a total current asset of $860.5 million as of September 30, 2024, down from $939.6 million at the end of 2023, a decrease of approximately 8%[23] - The accounts receivable decreased from $59.2 million as of December 31, 2023, to $50.0 million as of September 30, 2024, a decline of about 16%[23] - The company’s inventory net decreased from $44.8 million to $39.5 million, representing a reduction of approximately 12%[23] - The company’s long-term investments decreased from $9.2 million to $3.2 million, a decline of about 65%[23] - The company’s total liabilities amounted to $240.2 million as of September 30, 2024, compared to the previous figure of $286.3 million, indicating a decrease of approximately 16%[24] - The company’s total current liabilities decreased from $317.7 million to $240.2 million, reflecting a reduction of about 24%[24] Other Financial Metrics - The company reported a foreign exchange gain of $14.457 million for the three months ended September 30, 2024, compared to a gain of $4.852 million in the same period of 2023[26] - Research and development expenses for the three months ended September 30, 2024, were $65.982 million, an increase from $58.767 million in the same period of 2023[26] - The weighted average shares outstanding for basic and diluted loss per share was 981,687,390 for the three months ended September 30, 2024[26] - The company did not report any income tax expense for the periods ended September 30, 2024, and 2023[28]

Financial Performance - Net product revenue for Q3 2024 was $101.8 million, a 47% increase year-over-year, driven by VYVGART sales and renewals of NRDL listings for ZEJULA and NUZYRA[80]. - Total revenues for the three months ended September 30, 2024, were $102.3 million, a 48% increase from $69.2 million in 2023, and for the nine months, revenues were $289.9 million, up 44% from $200.9 million[99]. - Product revenue increased by $32.6 million (47%) and $88.2 million (44%) for the three and nine months ended September 30, 2024, respectively, primarily driven by increased sales of VYVGART and other products[101]. - ZEJULA sales for the three months ended September 30, 2024, were $48.2 million, a 16% increase from $41.6 million in 2023, while VYVGART sales surged by 458% to $27.3 million[102]. - The company reported a net loss of $41.7 million for the three months ended September 30, 2024, a decrease from a net loss of $69.2 million in the same period of 2023[121]. - Net loss for the three months ended September 30, 2024, was $41.7 million, a 40% improvement from a loss of $69.2 million in 2023, and for the nine months, the loss was $175.4 million, down 27% from $239.2 million[99]. Research and Development - The company anticipates continued significant investments in research and development to advance its pipeline of product candidates[93]. - ZL-1310, an investigational DLL3-antibody-drug conjugate, showed a 74% overall response rate in a Phase I study for extensive stage small cell lung cancer[83]. - KarXT demonstrated a statistically significant 9.2-point reduction in PANSS total score in a Phase III study for schizophrenia, with results expected to support a New Drug Application in early 2025[85]. - The company appointed Prista Charuworn, M.D., as Vice President of Immunology, Global R&D, to strengthen its R&D strategy[91]. - As of September 30, 2024, the company may incur up to $284.5 million in development and regulatory milestone payments for current clinical programs[97]. Expenses and Costs - Research and development expenses increased by $7.2 million (12%) for the three months ended September 30, 2024, primarily due to a $22.6 million increase in licensing fees[106]. - Cost of product revenue increased by $11.1 million (44%) and $34.8 million (49%) for the three and nine months ended September 30, 2024, respectively, due to rising sales volumes[103]. - Selling, general, and administrative expenses decreased by $1.3 million (2%) for the three months ended September 30, 2024, but increased by $17.1 million (9%) for the nine months[112]. - VYVGART, launched in September 2023, contributed to a $17.1 million increase in selling, general, and administrative expenses for the nine months ended September 30, 2024[113]. Cash and Investments - The company had cash and cash equivalents of $716.1 million as of September 30, 2024, expected to meet cash requirements for at least the next 12 months[138]. - Net cash provided by financing activities was $112.1 million in the nine months ended September 30, 2024, compared to a net cash used of $6.8 million in the same period of 2023[144]. - The company had short-term debt of approximately $113.0 million related to new debt arrangements[140]. - The company held short-term investments of $16.3 million as of December 31, 2023, compared to nil as of September 30, 2024[154]. - Net cash used in operating activities decreased by $24.2 million in the nine months ended September 30, 2024, primarily due to a $63.8 million reduction in net loss[142]. Foreign Currency and Credit Risk - Foreign currency gains for the three months ended September 30, 2024, were $14.5 million, a 198% increase from $4.9 million in 2023[99]. - Interest income for the three months ended September 30, 2024, was $9.0 million, a slight decrease of 2% from $9.2 million in 2023[99]. - The company does not currently have significant direct foreign exchange risk, as its transactions are primarily settled in RMB[149]. - The value of the company's ADSs and ordinary shares is affected by the exchange rates between U.S. dollars, HK dollars, and RMB[151]. - The company manages credit risk related to accounts receivable through ongoing monitoring and has historically collected receivables within credit terms[156].

Revenue Performance - Net product revenue for Q3 2024 reached $101.8 million, a 47% year-over-year increase from $69.2 million in Q3 2023[3]. - VYVGART sales were $27.3 million in Q3 2024, up from $4.9 million in Q3 2023, driven by its launch and listing on China's National Reimbursement Drug List[3][4]. - ZEJULA generated $48.2 million in Q3 2024, reflecting a 16% year-over-year growth from $41.6 million in Q3 2023[4]. - NUZYRA sales increased by 82% year-over-year to $10.0 million in Q3 2024, compared to $5.5 million in Q3 2023[5]. - Total revenues for Q3 2024 reached $102.3 million, a 47% increase compared to $69.2 million in Q3 2023[35]. - Product revenue for the nine months ended September 30, 2024, was $289.1 million, reflecting a 44% year-over-year growth from $200.9 million in the same period of 2023[40]. Expenses - Research and Development expenses were $66.0 million in Q3 2024, up from $58.8 million in Q3 2023, primarily due to increased upfront and milestone fees[6]. - Selling, General and Administrative expenses decreased to $67.2 million in Q3 2024 from $68.6 million in Q3 2023[7]. - Adjusted loss from operations for Q3 2024 was $48.2 million, compared to $59.7 million in Q3 2023, indicating a 19% reduction[41]. Net Loss and Financial Position - Net loss for Q3 2024 was $41.7 million, a significant improvement from a net loss of $69.2 million in Q3 2023[9]. - The company reported a net loss of $41.7 million for Q3 2024, an improvement from a net loss of $69.2 million in Q3 2023[37]. - Cash position as of September 30, 2024, was $716.1 million, down from $730.0 million as of June 30, 2024[9]. - Cash and cash equivalents decreased to $616.1 million as of September 30, 2024, down from $790.2 million at the end of 2023[34]. - Total current liabilities increased to $286.3 million as of September 30, 2024, compared to $203.1 million at the end of 2023[34]. - The company’s accumulated deficit grew to $2.37 billion as of September 30, 2024, from $2.20 billion at the end of 2023[34]. Future Outlook - Positive results from the China bridging study of KarXT for schizophrenia are expected to lead to a regulatory submission in early 2025[2][14]. - Zai Lab anticipates three product launches in mainland China by the end of 2024 and up to four potential regulatory submissions to the NMPA in the next six months[1]. - Zai Lab anticipates continued revenue growth and aims to achieve profitability through its growth strategy and product pipeline[31]. - The company experienced foreign currency gains of $14.5 million in Q3 2024, compared to gains of $4.9 million in Q3 2023[35].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of $60 for the US stock and HK$47 for the Hong Kong stock [1][3]. Core Insights - The initial efficacy and safety data for ZL-1310 (DLL3 ADC) in the 2L+ ES-SCLC indication are excellent, significantly boosting investor confidence in the company's R&D pipeline [1]. - ZL-1310 demonstrated a 74% overall response rate (ORR) in the global Phase 1 trial, with a 100% ORR in patients with brain metastases [1]. - The company plans to accelerate the development of ZL-1310 for 2L+ ES-SCLC and aims to communicate with the FDA regarding the accelerated approval pathway [1]. Financial Performance - The projected revenue for 2023 is $267 million, with a year-on-year growth of 24% [2][9]. - The company is expected to incur a net loss of $335 million in 2023, improving to a loss of $137 million by 2025 [2][9]. - The revenue is forecasted to grow significantly, reaching $995 million by 2026, with a compound annual growth rate (CAGR) of 53.3% from 2023 to 2026 [2][9]. Market Expectations - The current stock price is $28.9, with a potential upside of 107% to the target price of $60 [3][5]. - The stock has a 52-week price range of $13.4 to $31.2, indicating volatility and potential for growth [3][5]. Clinical Data Comparison - ZL-1310's ORR of 74% is higher than that of competitors like YL201 (68% ORR) and ZG006 (67% ORR), showcasing its competitive edge in the market [1][8]. - The safety profile of ZL-1310 is superior, with lower rates of ≥3 grade treatment-related adverse events (TRAEs) compared to YL201 [1][8].

Financial Performance - The company reported a significant increase in revenue, achieving $150 million in Q2 2024, representing a 25% year-over-year growth[9]. - For the six months ending June 30, 2024, product net revenue was $187.3 million, a 42% increase compared to the same period last year, primarily driven by increased sales of Weiwei Jia since its launch in September 2023 and its inclusion in the national medical insurance catalog in January 2024[12]. - Total revenue reached $187.653 million, up 43% from $131.661 million in the same period last year[25]. - The company reported a net loss before tax of $133.748 million, a 21% improvement from $170.039 million in the previous year[24]. - The company incurred a net loss of $133,748,000 for the six months ended June 30, 2024, an improvement from a net loss of $170,039,000 in the same period of 2023, reflecting a reduction of approximately 21.4%[112]. - The company reported a basic and diluted loss per share of $0.14 for the six months ended June 30, 2024, compared to a loss of $0.18 for the same period in 2023[111]. Product Development and Launches - New product launches included a groundbreaking drug expected to enter the market in Q4 2024, with projected sales of $50 million in the first year[9]. - Clinical trial results for a key product showed a 75% efficacy rate, surpassing industry expectations[9]. - The company is currently recruiting patients for global phase I studies of ZL-1310 and ZL-1218 in the US and Greater China[14]. - The company has ongoing key clinical studies for several candidate products, including Adagrasib and Tisotumab Vedotin, with significant regulatory milestones achieved[13][14]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 15% market share by the end of 2025[9]. - The company plans to allocate 30% of its budget to marketing efforts aimed at increasing brand awareness in Asia[9]. - Zai Lab announced plans for market expansion into new regions, aiming to increase its market share by DD% over the next year[167]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and strengthen its market position[167]. Research and Development - The company invested $20 million in new technology development, focusing on improving drug delivery systems[9]. - Research and development expenditures are expected to remain high as the company invests in advancing its pipeline of potential best-in-class and first-in-class products[19]. - The company anticipates significant costs related to research and development and commercialization activities in the coming years[12]. Financial Guidance and Projections - The company provided guidance for Q3 2024, projecting revenue between $160 million and $170 million, indicating a growth rate of 20% to 25%[9]. - The financial performance is expected to fluctuate quarterly and annually, depending on the success of commercialized products and the level of R&D expenditures[12]. - The company aims to achieve overall profitability by the end of 2025[23]. Shareholder and Corporate Governance - The company is committed to maintaining shareholder trust through its Trust for Life strategy, focusing on improving human health and ethical business practices[23]. - The company has established a Chief Independent Director to enhance corporate governance while the CEO also serves as the Chairman[92]. - The company emphasized its commitment to shareholder value, with plans to implement a share buyback program in the near future[167]. Cash Flow and Financial Position - Cash and cash equivalents, along with restricted cash, totaled $731.2 million as of June 30, 2024, down from $807.6 million at the end of 2023[38]. - The company has raised approximately $164.6 million through private placements and has sufficient cash to meet operational needs for at least the next 12 months[39]. - The company reported cash flows from operating activities used amounted to $132,279,000 for the six months ended June 30, 2024, compared to $127,989,000 for the same period in 2023[116]. Employee Compensation and Costs - Employee compensation and related costs increased by $10.4 million (12%) to $94.2 million for the six months ended June 30, 2024, primarily driven by an increase in headcount[33]. - Total employee compensation costs for the first half of 2024 were $153.4 million, an increase from $141.4 million in the first half of 2023[51]. Regulatory and Compliance - The management emphasized the importance of regulatory approvals, with three key submissions expected in the next six months[9]. - The company has confirmed compliance with its own securities trading policy during the reporting period[93]. Stock Options and Equity Incentives - The company has four equity incentive plans, with a maximum potential issuance of 121,522,950 shares as of June 30, 2024[61]. - The total number of stock options outstanding as of June 30, 2024, is 28,684,640[63]. - The company has granted restricted stock units totaling 14,697,950 shares during the reporting period[84]. Miscellaneous - The company is focused on addressing unmet medical needs in oncology, autoimmune diseases, infectious diseases, and central nervous system disorders through innovative product discovery and development[118]. - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[94].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔 任何責任。 Zai Lab Limited 再鼎醫藥有限公司 * （於開曼群島註冊成立的有限公司） （股份代號：9688） 截 至 2024 年 6 月 3 0 日止六個月 中期業績公告 本公司謹此公佈本公司於報告期的未經審計簡明合併業績，連同2023年同期的比較數 字，該等資料乃根據美國公認會計準則編製並由審核委員會審閱。本公告列載本公司 2024年中期報告全文，並符合香港上市規則中有關中期業績初步公告附載的資料之相關 要求。 財務摘要 截至2024年6月30日止六個月與截至2023年6月30日止六個月比較（以美元計） • 產品收入淨額增加55.6百萬美元（或42%）至187.3百萬美元，主要受衛偉迦® （艾加 莫德α注射液）自2023年9月上市及於2024年1月被納入國家醫保目錄以來銷售額增 加以及則樂®、紐再樂® 及擎樂® 的銷售額增加所推動。 • 研發開支減少8.9百萬美元（或7%）至116.3百萬美元， ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3]. Core Views - The company is transitioning from a license-in model to an innovation-driven approach, establishing a strong product pipeline and commercializing five products by the end of 2023, generating revenue of $267 million [1][11]. - The company aims for a compound annual growth rate (CAGR) of approximately 50% in revenue from 2023 to 2028, targeting $2 billion in revenue by 2028 and profitability by the end of 2025 [1][21]. Financial Projections - Revenue projections for 2024, 2025, and 2026 are $390 million, $583 million, and $866 million, respectively, with year-over-year growth rates of 46.11%, 49.51%, and 48.66% [2][6]. - The net profit for the same years is projected to be -$312 million, -$184 million, and $34 million, indicating a path towards profitability by 2026 [2][6]. Product Pipeline and Market Position - The company has established over 50 clinical-stage or planned clinical-stage pipelines across oncology, infectious diseases, central nervous system disorders, and autoimmune diseases, with eight products approved in China [16][19]. - Key products include Niraparib, a PARP inhibitor for ovarian cancer, and the first approved tumor-treating fields therapy for glioblastoma, showcasing the company's competitive advantages in innovative therapies [1][22][23]. Strategic Development - The company is focusing on a dual strategy of external licensing and internal research and development, with several products entering clinical research phases [1][14]. - The management team has extensive experience in the biopharmaceutical industry, enhancing the company's capability to navigate the complex drug development landscape [12][13].